Macungie, PA, United States of America

Christophe Guillon

This inventor holds 5 USPTO granted patents. Top assignees: Lehigh University, Rutgers, The State University of New Jersey, University of Medicine and Dentistry of New Jersey. Active years: 2001-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christophe Guillon. Retrieved from https://idiyas.com/inventor/christophe-guillon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 60.0

Average Co-Inventor Count = 7.2

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Bethlehem, PA (US) (2001 - 2009)
  • Macungie, PA (US) (2016 - 2020)

Company Filing History:


Years Active: 2001-2020

Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Christophe Guillon

Introduction

Christophe Guillon is a notable inventor based in Macungie, PA (US). He has made significant contributions to the field of therapeutics, holding a total of 5 patents. His work focuses on developing innovative solutions for clinical conditions that require inflammation suppression and cholinergic intervention.

Latest Patents

One of his latest patents is titled "Unique dual-action therapeutics." This patent discloses a new family of therapeutics that provides a controlled-release delivery platform for non-steroidal anti-inflammatory agents on an ester or an ester-carbonate backbone. These agents serve as reversible inhibitors of acetylcholinesterase, making them useful for various clinical conditions. The compounds are characterized by a general formula where n can be 0 or 1, and X can be C, Si, or N+. Notable non-steroidal anti-inflammatory drugs (NSAIDs) mentioned include ibuprofen, naproxen, indomethacin, and diclofenac. Other embodiments of this invention are also disclosed.

Another significant patent is focused on "Furyl and thienyl triazole derivatives and therapeutic uses thereof." This patent describes nitric oxide biosynthesis-inhibiting anti-inflammatory and anti-microbial compounds. The compounds are defined by specific formulas, wherein R1 and R2 can be independently selected from various substituted thienyl and furyl groups. The treatment methods utilizing these compounds, along with their synthesis methods, are also disclosed.

Career Highlights

Christophe Guillon has had a distinguished career, working at reputable institutions such as Rutgers, the State University of New Jersey, and Lehigh University. His academic and research endeavors have significantly contributed to advancements in therapeutic innovations.

Collaborations

Throughout his career, Guillon has collaborated with esteemed colleagues, including Ned D Heindel and Jeffrey D Laskin. These collaborations have further enriched his research and development efforts in the field of therapeutics.

Conclusion

Christophe Guillon's innovative work in therapeutics showcases his dedication to advancing medical science. His patents reflect a commitment to addressing critical clinical needs through novel solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…